| Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology OD Howes, R McCutcheon, O Agid, A De Bartolomeis, NJM Van Beveren, ... American Journal of Psychiatry 174 (3), 216-229, 2017 | 829 | 2017 |
| Cannabidiol for the treatment of psychosis in Parkinson’s disease AW Zuardi, JAS Crippa, JEC Hallak, JP Pinto, MHN Chagas, ... Journal of Psychopharmacology 23 (8), 979-983, 2009 | 415 | 2009 |
| Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco–magnetic resonance imaging study JFW Deakin, J Lees, S McKie, JEC Hallak, SR Williams, SM Dursun Archives of general psychiatry 65 (2), 154-164, 2008 | 350 | 2008 |
| Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment IB Chaudhry, J Hallak, N Husain, F Minhas, J Stirling, P Richardson, ... Journal of psychopharmacology 26 (9), 1185-1193, 2012 | 323 | 2012 |
| Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. K Black, C Shea, S Dursun, S Kutcher Journal of Psychiatry and Neuroscience 25 (3), 255, 2000 | 301 | 2000 |
| Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions L Urichuk, TI Prior, S Dursun, G Baker Current drug metabolism 9 (5), 410-418, 2008 | 284 | 2008 |
| Cannabidiol monotherapy for treatment-resistant schizophrenia AW Zuardi, JEC Hallak, SM Dursun, SL Morais, RF Sanches, RE Musty, ... Journal of Psychopharmacology 20 (5), 683-686, 2006 | 274 | 2006 |
| Neurological complications of psychiatric drugs: clinical features and management PM Haddad, SM Dursun Human Psychopharmacology: Clinical and Experimental 23 (S1), S15-S26, 2008 | 262 | 2008 |
| An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria JW Radomski, SM Dursun, MA Reveley, SP Kutcher Medical hypotheses 55 (3), 218-224, 2000 | 255 | 2000 |
| Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis L Hartling, AM Abou-Setta, S Dursun, SS Mousavi, D Pasichnyk, ... Annals of internal medicine 157 (7), 498-511, 2012 | 234 | 2012 |
| Cholesterol and mental disorder PF Boston, SM Dursun, MA Reveley The British Journal of Psychiatry 169 (6), 682-689, 1996 | 193 | 1996 |
| ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements MRG Brown, GS Sidhu, R Greiner, N Asgarian, M Bastani, PH Silverstone, ... Frontiers in systems neuroscience 6, 69, 2012 | 182 | 2012 |
| An overview of animal models related to schizophrenia IR Winship, SM Dursun, GB Baker, PA Balista, L Kandratavicius, ... The Canadian Journal of Psychiatry 64 (1), 5-17, 2019 | 180 | 2019 |
| Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study SM Dursun, JFW Deakin Journal of Psychopharmacology 15 (4), 297-301, 2001 | 171 | 2001 |
| Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness J Hamill, J Hallak, SM Dursun, G Baker Current neuropharmacology 17 (2), 108-128, 2019 | 169 | 2019 |
| Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial JEC Hallak, JP Maia-de-Oliveira, J Abrao, PR Evora, AW Zuardi, ... JAMA psychiatry 70 (7), 668-676, 2013 | 154 | 2013 |
| Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation A Briggs, D Wild, M Lees, M Reaney, S Dursun, D Parry, J Mukherjee Health and quality of life outcomes 6 (1), 1-9, 2008 | 137 | 2008 |
| Clozapine plus lamotrigine in treatment-resistant schizophrenia SM Dursun, D McIntosh, H Milliken Archives of general psychiatry 56 (10), 950-950, 1999 | 134 | 1999 |
| Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers D Matveychuk, RK Thomas, J Swainson, A Khullar, MA MacKay, ... Therapeutic advances in psychopharmacology 10, 2045125320916657, 2020 | 117 | 2020 |
| Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder L Riske, RK Thomas, GB Baker, SM Dursun Therapeutic advances in psychopharmacology 7 (2), 85-89, 2017 | 116 | 2017 |
João AbrãoProfessor da Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloBestätigte E-Mail-Adresse bei fmrp.usp.br
